# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Joseph Pantginis reiterates Pharming (NASDAQ:PHAR) with a Buy and maintains $37 price target.
Outlook/Summary For 2024, the Company anticipates: Total revenues between US$280 million and US$295 million (14% to 20% gro...
Pharming (NASDAQ:PHAR) reported quarterly losses of $(0.00) per share. The company reported $74.10 million in sales this quarte...